Business Standard

Pfizer and BioNTech start late-stage study of lead Covid-19 shot

The move pushes the New York-based pharmaceutical giant and its German partner closer to bringing a vaccine to market, and places them alongside frontrunners like Moderna Inc

covid-19, vaccine, coronavirus
Premium

Pfizer and BioNTech said that they had selected a lead vaccine candidate from within a broader development programme and will proceed with a later-stage safety and efficacy trial of the experimental shot in a two-dose regimen

Bloomberg
Pfizer and BioNTech SE said they’ve begun a later-stage trial for their top coronavirus vaccine candidate and set a goal of submitting it for regulatory review as soon as October — one of the most ambitious timelines to date.
 
The move pushes the New York-based pharmaceutical giant and its German partner closer to bringing a vaccine to market, and places them alongside frontrunners like Moderna Inc, which anno­unced earlier Monday that it had started its own large, final-stage trial of a shot based on similar technology.
 
Pfizer and BioNTech said that they had selected a lead vaccine candidate

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Jul 29 2020 | 1:27 AM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com